Aldesleukin (Proleukin)

Biologic response modifier (interleukin-2)

Aldesleukin (Proleukin)

Forms and strengths
Form: TabletStrength: 22 million International Units (1.3 mg) per vial
Print

Indication

  • Aldesleukin is indicated for the treatment of adults with metastatic renal cell carcinoma.
  • Aldesleukin is indicated for the treatment of adults with metastatic malignant melanoma.
  • Careful patient selection, including cardiac and pulmonary function testing, is required before starting treatment, since therapy is associated with severe, potentially life-threatening side effects.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.